This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).

NCT03713619 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

544

Enrollment

INDUSTRY

Sponsor class

Conditions

Hidradenitis Suppurativa

Interventions

DRUG: secukinumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals